NHS to receive £8m from Aspen over anti-competitive practices
15-08-2019
CMA accuses 4 pharma companies of anti-competitive conduct
24-05-2019
Sureeporn Teerasatean / Shutterstock.com
African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority (CMA).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CMA, competition, antitrust, NHS, Competition and Markets Authority, drug suppliers, Aspen, competition settlement, Amilco, Tiofarma
